Ironwood Pharmaceuticals, Inc. (IRWD) – What Are Analysts Thinking About This Stock?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $6.23.

Several equities research analysts have recently commented on the company. Weiss Ratings raised Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Zacks Research cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 7th. Finally, Jefferies Financial Group upgraded Ironwood Pharmaceuticals to a “hold” rating in a report on Friday, September 25th.

Ironwood Pharmaceuticals Stock Performance

NASDAQ IRWD opened at $4.87 on Friday. Ironwood Pharmaceuticals has a 1 year low of $2.85 and a 1 year high of $5.78. The business’s fifty day moving average is $3.95 and its two-hundred day moving average is $3.96. The stock has a market capitalization of $804.72 million, a P/E ratio of 5.34 and a beta of 0.25.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.04. The business had revenue of $133.04 million during the quarter, compared to analyst estimates of $119.99 million. Ironwood Pharmaceuticals had a negative return on equity of 81.40% and a net margin of 37.38%. On average, research analysts forecast that Ironwood Pharmaceuticals will post 1.10 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its position in Ironwood Pharmaceuticals by 529.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,082,055 shares of the biotechnology company’s stock worth $7,307,000 after purchasing an additional 1,751,219 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Ironwood Pharmaceuticals in the second quarter valued at $2,142,000. Pacer Advisors Inc. purchased a new stake in shares of Ironwood Pharmaceuticals in the first quarter valued at $3,982,000. CWA Asset Management Group LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 71.7% in the third quarter. CWA Asset Management Group LLC now owns 498,643 shares of the biotechnology company’s stock valued at $1,980,000 after purchasing an additional 208,277 shares in the last quarter. Finally, Globeflex Capital L P acquired a new stake in shares of Ironwood Pharmaceuticals in the second quarter worth $1,094,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing treatments for gastrointestinal diseases. Founded in 1998, the company is headquartered in Boston, Massachusetts. Its principal product is LINZESS (linaclotide), a prescription medicine for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. Ironwood and AbbVie collaborate on the product’s U.S. commercialization, while licensing partners make linaclotide available in other markets under regional brand names.